ISSN: 2641-9459
Authors: Nadiya P*
Groundbreaking research into a new biomarker that can indicate cardiac damage and mortality in pulmonary hypertension patients has been identified in a recent study by Tzouvelekis, et al. on ‘S100A12 [1] as a marker of worse cardiac output and mortality in pulmonary hypertension’. Biomarkers are objectively measured characteristics that provide an indication of normal biological processes, pathogenic processes or processes in the body that occur as a pharmaceutical response to treatment [2]. Findings of this study showed that biomarker S100A12 is elevated in pulmonary hypertension patients compared to healthy individuals [1]. This biomarker has emerged to be of value in various other inflammatory diseases, thus leading this study to be highly significant as results show that S100A12 is a determining factor and prognostic indicator of pulmonary hypertension.
Keywords:
